vs
Side-by-side financial comparison of Jazz Pharmaceuticals plc (JAZZ) and MODINE MANUFACTURING CO (MOD). Click either name above to swap in a different company.
Jazz Pharmaceuticals plc is the larger business by last-quarter revenue ($1.2B vs $805.0M, roughly 1.5× MODINE MANUFACTURING CO). Jazz Pharmaceuticals plc runs the higher net margin — 17.0% vs -5.9%, a 22.9% gap on every dollar of revenue. On growth, MODINE MANUFACTURING CO posted the faster year-over-year revenue change (30.5% vs 10.1%). Jazz Pharmaceuticals plc produced more free cash flow last quarter ($345.8M vs $-17.1M). Over the past eight quarters, MODINE MANUFACTURING CO's revenue compounded faster (15.5% CAGR vs 15.2%).
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
Modine Manufacturing is a thermal management company established in 1916 in the United States. The company started as Modine Manufacturing Company by Arthur B Modine who patented the Spirex radiator for tractors. The Modine company manufactured the Turbotube radiator for Ford Model T cars. The company built the world's first vehicular wind tunnel in Racine, Wisconsin in 1941. During WWII, Modine manufactured aftercoolers for the P-51 Mustang fighter plane. After WWII, Modine introduced the Ai...
JAZZ vs MOD — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.2B | $805.0M |
| Net Profit | $203.5M | $-47.4M |
| Gross Margin | — | 23.1% |
| Operating Margin | 21.2% | 11.1% |
| Net Margin | 17.0% | -5.9% |
| Revenue YoY | 10.1% | 30.5% |
| Net Profit YoY | 6.5% | -215.6% |
| EPS (diluted) | $3.34 | $-0.90 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.2B | $805.0M | ||
| Q3 25 | $1.1B | $738.9M | ||
| Q2 25 | $1.0B | $682.8M | ||
| Q1 25 | $897.8M | $647.2M | ||
| Q4 24 | $1.1B | $616.8M | ||
| Q3 24 | $1.1B | $658.0M | ||
| Q2 24 | $1.0B | $661.5M | ||
| Q1 24 | $902.0M | $603.5M |
| Q4 25 | $203.5M | $-47.4M | ||
| Q3 25 | $251.4M | $44.4M | ||
| Q2 25 | $-718.5M | $51.2M | ||
| Q1 25 | $-92.5M | $49.6M | ||
| Q4 24 | $191.1M | $41.0M | ||
| Q3 24 | $215.1M | $46.1M | ||
| Q2 24 | $168.6M | $47.3M | ||
| Q1 24 | $-14.6M | $25.8M |
| Q4 25 | — | 23.1% | ||
| Q3 25 | — | 22.3% | ||
| Q2 25 | — | 24.2% | ||
| Q1 25 | — | 25.6% | ||
| Q4 24 | — | 24.3% | ||
| Q3 24 | — | 25.2% | ||
| Q2 24 | — | 24.6% | ||
| Q1 24 | — | 22.4% |
| Q4 25 | 21.2% | 11.1% | ||
| Q3 25 | 5.1% | 9.9% | ||
| Q2 25 | -65.6% | 11.1% | ||
| Q1 25 | -6.2% | 11.5% | ||
| Q4 24 | 17.5% | 9.6% | ||
| Q3 24 | 24.7% | 11.4% | ||
| Q2 24 | 19.5% | 11.2% | ||
| Q1 24 | 7.3% | 7.8% |
| Q4 25 | 17.0% | -5.9% | ||
| Q3 25 | 22.3% | 6.0% | ||
| Q2 25 | -68.7% | 7.5% | ||
| Q1 25 | -10.3% | 7.7% | ||
| Q4 24 | 17.6% | 6.6% | ||
| Q3 24 | 20.4% | 7.0% | ||
| Q2 24 | 16.5% | 7.2% | ||
| Q1 24 | -1.6% | 4.3% |
| Q4 25 | $3.34 | $-0.90 | ||
| Q3 25 | $4.08 | $0.83 | ||
| Q2 25 | $-11.74 | $0.95 | ||
| Q1 25 | $-1.52 | $0.92 | ||
| Q4 24 | $2.97 | $0.76 | ||
| Q3 24 | $3.42 | $0.86 | ||
| Q2 24 | $2.49 | $0.88 | ||
| Q1 24 | $-0.23 | $0.48 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.4B | $98.7M |
| Total DebtLower is stronger | $5.4B | $570.7M |
| Stockholders' EquityBook value | $4.3B | $1.1B |
| Total Assets | $11.7B | $2.5B |
| Debt / EquityLower = less leverage | 1.24× | 0.51× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.4B | $98.7M | ||
| Q3 25 | $1.3B | $83.8M | ||
| Q2 25 | $1.2B | $124.5M | ||
| Q1 25 | $1.9B | $71.6M | ||
| Q4 24 | $2.4B | $83.8M | ||
| Q3 24 | $2.2B | $78.6M | ||
| Q2 24 | $1.4B | $72.9M | ||
| Q1 24 | $1.4B | $60.1M |
| Q4 25 | $5.4B | $570.7M | ||
| Q3 25 | $5.4B | $525.8M | ||
| Q2 25 | $5.4B | $482.1M | ||
| Q1 25 | $5.4B | $296.7M | ||
| Q4 24 | $6.1B | $330.0M | ||
| Q3 24 | $6.1B | $359.1M | ||
| Q2 24 | $5.7B | $405.7M | ||
| Q1 24 | $5.7B | $399.9M |
| Q4 25 | $4.3B | $1.1B | ||
| Q3 25 | $4.0B | $1.1B | ||
| Q2 25 | $3.7B | $1.0B | ||
| Q1 25 | $4.2B | $910.2M | ||
| Q4 24 | $4.1B | $855.1M | ||
| Q3 24 | $4.2B | $858.8M | ||
| Q2 24 | $3.8B | $788.4M | ||
| Q1 24 | $3.7B | $747.6M |
| Q4 25 | $11.7B | $2.5B | ||
| Q3 25 | $11.4B | $2.4B | ||
| Q2 25 | $10.9B | $2.2B | ||
| Q1 25 | $11.5B | $1.9B | ||
| Q4 24 | $12.0B | $1.8B | ||
| Q3 24 | $12.3B | $1.9B | ||
| Q2 24 | $11.4B | $1.9B | ||
| Q1 24 | $11.3B | $1.9B |
| Q4 25 | 1.24× | 0.51× | ||
| Q3 25 | 1.35× | 0.50× | ||
| Q2 25 | 1.45× | 0.48× | ||
| Q1 25 | 1.29× | 0.33× | ||
| Q4 24 | 1.49× | 0.39× | ||
| Q3 24 | 1.47× | 0.42× | ||
| Q2 24 | 1.52× | 0.51× | ||
| Q1 24 | 1.54× | 0.53× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $362.5M | $24.7M |
| Free Cash FlowOCF − Capex | $345.8M | $-17.1M |
| FCF MarginFCF / Revenue | 28.9% | -2.1% |
| Capex IntensityCapex / Revenue | 1.4% | 5.2% |
| Cash ConversionOCF / Net Profit | 1.78× | — |
| TTM Free Cash FlowTrailing 4 quarters | $1.3B | $-20.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $362.5M | $24.7M | ||
| Q3 25 | $474.6M | $1.4M | ||
| Q2 25 | $88.9M | $27.7M | ||
| Q1 25 | $429.8M | $54.8M | ||
| Q4 24 | $398.6M | $60.7M | ||
| Q3 24 | $398.7M | $57.3M | ||
| Q2 24 | $331.4M | $40.5M | ||
| Q1 24 | $267.2M | $39.6M |
| Q4 25 | $345.8M | $-17.1M | ||
| Q3 25 | $459.4M | $-30.5M | ||
| Q2 25 | $75.9M | $200.0K | ||
| Q1 25 | $415.9M | $27.1M | ||
| Q4 24 | $385.3M | $44.7M | ||
| Q3 24 | $388.0M | $43.8M | ||
| Q2 24 | $324.3M | $13.7M | ||
| Q1 24 | $260.3M | $-4.3M |
| Q4 25 | 28.9% | -2.1% | ||
| Q3 25 | 40.8% | -4.1% | ||
| Q2 25 | 7.3% | 0.0% | ||
| Q1 25 | 46.3% | 4.2% | ||
| Q4 24 | 35.4% | 7.2% | ||
| Q3 24 | 36.8% | 6.7% | ||
| Q2 24 | 31.7% | 2.1% | ||
| Q1 24 | 28.9% | -0.7% |
| Q4 25 | 1.4% | 5.2% | ||
| Q3 25 | 1.3% | 4.3% | ||
| Q2 25 | 1.2% | 4.0% | ||
| Q1 25 | 1.5% | 4.3% | ||
| Q4 24 | 1.2% | 2.6% | ||
| Q3 24 | 1.0% | 2.1% | ||
| Q2 24 | 0.7% | 4.1% | ||
| Q1 24 | 0.8% | 7.3% |
| Q4 25 | 1.78× | — | ||
| Q3 25 | 1.89× | 0.03× | ||
| Q2 25 | — | 0.54× | ||
| Q1 25 | — | 1.10× | ||
| Q4 24 | 2.09× | 1.48× | ||
| Q3 24 | 1.85× | 1.24× | ||
| Q2 24 | 1.97× | 0.86× | ||
| Q1 24 | — | 1.53× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
JAZZ
| Xywav | $465.5M | 39% |
| Total Oncology | $337.8M | 28% |
| Rylaze Enrylaze | $108.2M | 9% |
| Zepzelca | $90.4M | 8% |
| Product And Services Royalties And Contract Revenue | $65.5M | 5% |
| High Sodium AG Oxybate Product Royalty Revenue | $55.7M | 5% |
| Xyrem | $37.8M | 3% |
| Vyxeos | $34.7M | 3% |
| Ziihera | $8.5M | 1% |
| Other Products | $2.8M | 0% |
| Sativex | $1.5M | 0% |
MOD
| Data Centers | $296.9M | 37% |
| Performance Technologies | $266.0M | 33% |
| Hvac Technologies | $107.1M | 13% |
| Air Cooled | $92.4M | 11% |
| Lb White | $25.6M | 3% |
| Climate By Design | $10.2M | 1% |
| Absolutaire | $7.0M | 1% |
